Search

Search Constraints

You searched for: Author/Creator Tewari, Devansu

Search Results

1. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Issue 12 (December 2020)

2. Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. Issue 3 (March 2021)

3. Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. Issue 3 (March 2021)

4. Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer. Issue 8 (August 2015)

8. TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study. (4th December 2022)